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Abstract Little is known about the magnitude of the
association between infective endocarditis and cancer, and
about the natural history of cancer patients with concomi-
tant diagnosis of infective endocarditis. We used the
SEER-Medicare linked database to identify individuals
aged 65 years or more diagnosed with colorectal, lung,
breast, or prostate cancer, and without any cancer diagnosis
(5 % random Medicare sample from SEER areas) between
1992 and 2009. We identified infective endocarditis from
the ICD-9 diagnosis of each admission recorded in the
Medpar file and its incidence rate 90 days around cancer
diagnosis. We also estimated the overall survival and CRC-
specific survival after a concomitant diagnosis of infective
endocarditis. The peri-diagnostic incidence of infective
endocarditis was 19.8 cases per 100,000 person-months for
CRC, 5.7 cases per 100,000 person-months for lung cancer,
1.9 cases per 100,000 person-months for breast cancer, 4.1
cases per 100,000 person-months for prostate cancer and
2.4 cases per 100,000 person-months for individuals
without cancer. Two-year overall survival was 46.4 %
(95 % CI 39.5, 54.5 %) for stage I–III CRC patients with
concomitant endocarditis and 73.1 % (95 % CI 72.9,
73.3 %) for those without it. In this elderly population, the
incidence of infective endocarditis around CRC diagnosis
was substantially higher than around the diagnosis of lung,
breast and prostate cancers. A concomitant diagnosis of
infective endocarditis in patients with CRC diagnosis is
associated with shorter survival.
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Introduction
Colorectal, lung, breast, and prostate cancer account for
about half of cancers in the United States and in Europe,
with more than 800,000 and 1,370,000 new diagnoses per
year respectively [1, 2]. The care of these patients is
complex and invasive, particularly during the initial year
after diagnosis. Concurrent infections may interfere with
patient care and lead to worse outcomes. In particular,
among patients with colorectal cancer (CRC), Streptococ-
cus gallolyticus (formerly named Streptococcus bovis
biotype I) appears to be associated with an increased risk of
infective endocarditis [3].
The association between CRC and endocarditis was first
proposed decades ago [4], and is supported by several case
series [5] and small case–control studies [6–8]. A meta-
analysis of these case–control studies found a strong
association (odds ratio 14.5, 95 % confidence interval
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5.7–37.6), but it was based on only 16 CRC patients with
endocarditis [9] and could not provide information about
the incidence of endocarditis around CRC diagnosis. Fur-
ther, few data exist about the association between endo-
carditis and the outcomes of CRC patients [10], or between
endocarditis and other tumor sites [11].
Here we present the first large-scale prospective study of
peridiagnostic incidence of endocarditis among patients
with colorectal, breast, lung, and prostate cancer. We also
evaluate the association between peridiagnostic endo-
carditis and the prognosis of patients with CRC.
Methods
Study population
Our study population was extracted from the SEER-
Medicare data, a linkage of patient demographic and
tumor-specific variables collected by 17 SEER cancer
registries across 12 states of the United States with
Medicare claim files from the Centers for Medicare and
Medicaid Services [12]. SEER data are summarized in the
Patient Entitlement and Diagnosis Summary File
(PEDSF), which is linked with 100 % of Medicare claims.
For the current study we used Medicare claims from the
Inpatient, Outpatient, Home Health Agency (HHA), Dur-
able Medical Equipment (DME), Medpar and National
Claims History (NCH) files. To identify the date of cancer
diagnosis we used the SEER date of diagnosis, which is
the month, and year the tumor was first diagnosed, clin-
ically or microscopically, by a recognized medical prac-
titioner [13].
We included patients with histological diagnosis of
invasive colorectal adenocarcinoma, lung cancer, breast
cancer, or prostate cancer between 1992 and 2009, and
who were enrolled in Medicare parts A and B and not in
an health maintenance organization during the year before
diagnosis. As a control group, we included patients
without cancer using a random 5 % sample of Medicare
beneficiaries living in areas with SEER registries. We
excluded patients with cancers reported by nursing home/
hospice, autopsy, or death certificate, and those with an
endocarditis diagnosis 12 or more months before cancer
diagnosis.
We identified endocarditis from the principal or sec-
ondary ICD-9 diagnosis (see codes in table A1) of each
admission recorded in the Medpar file [14]. From the
PEDSF file, we determined demographic characteristics
(age, sex, race, urbanicity), tumor features (TNM stage,
grade of differentiation, SEER date of diagnosis) and
census tract features (census region, percentage of black
population, percentage of residents living below the
poverty level, percentage of residents aged 25 or older with
less than 12 years of education, percentage of residents
speaking English not well/not at all at age 65?, median
income). We summarized comorbidity burden using the
Deyo–Charlson–Klabunde comorbidity index [15], derived
from the inpatient and outpatient Medicare claims for the
period between 12 months to the month before SEER date
of diagnosis. We extracted cancer-directed diagnostic tests
and therapy (colonoscopy, colectomy, chemotherapy) from
the NCH, Outsaf, Medpar and DME files (see codes in
table A1) and admissions in the year following cancer
diagnosis from the Medpar file. We also extracted the
colorectal cancer sentinel sign/symptom (anemia, gas-
trointestinal bleeding, gastrointestinal symptoms, large
bowel obstruction, see codes in table A1) from claims
issued during the 3 months previous SEER date of diag-
nosis. As falsification tests (negative controls for endo-
carditis), we examined the risk of two other serious
infections that are unlikely to be related to either CRC or
CRC care, i.e., pyelonephritis and meningitis.
Data analysis
We followed patients from 1 year before cancer diagnosis
(random reference date for the non-cancer cohort) until
they died, stopped fulfilling the inclusion criteria, or
reached the administrative end of follow-up (December
31st, 2010). In our main analyses, we computed the peri-
diagnostic incidence rate of endocarditis between 90 days
before and 90 after cancer diagnosis: number of endo-
carditis diagnoses divided by number of person-months in
that time period. For lung, breast and prostate cancer, we
standardized the rate by the age (B70, 71–75, 76–85,[85)
and sex (for lung cancer only) distribution of CRC patients.
We also plotted the monthly incidence rate of endocarditis
from -12 to ?24 months from cancer diagnosis.
We defined overall survival and cancer-related survival
as the time from SEER date of diagnosis to death by any
cause or cancer respectively. We classified patients as
having a concomitant diagnosis of endocarditis if they were
diagnosed with endocarditis between 90 days before and
90 days after cancer diagnosis, and as having no con-
comitant diagnosis of endocarditis otherwise. We con-
structed Kaplan–Meier curves for survival and cancer-
related survival by concomitant endocarditis, and estimated
the hazard ratios for endocarditis versus no endocarditis
using a Cox model adjusted by sex, age, stage, comorbidity
score, structural cardiac condition and presence of an
intravascular device. We used a non-parametric bootstrap
based on 1000 resamplings to compute 95 % confidence
intervals for survival differences at 24 months of follow-
up. We used SAS version 9.4 (SAS Institute, Cary, NC)
and R [16].
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Results
There were 1835 new cases of endocarditis among cancer
patients (Fig. 1). For CRC patients, the peri-diagnostic
endocarditis incidence rate was 19.8 cases per 100,000
person-months (95 % CI 17.0–22.6). The corresponding
rates were much lower for lung, breast, and prostate cancer,
and for individuals without cancer (Table 1). In contrast,
the incidence of peri-diagnostic pyelonephritis and
meningitis did not substantially differ by cancer site and
were higher than in patients without cancer (Supplemen-
tary Table A2). The endocarditis rate was highest during
the month of diagnosis for both CRC (42.1 cases per
100,000 person-months, 95 % CI 32.3, 52.0) and lung
cancer (15.6 cases per 100,000 person-months, 95 % CI
10.2, 21.0), but not for breast and prostate cancer (Fig. 2).
The use of colonoscopy increases after admission due to an
endocarditis (Supplementary Figure A1).
CRC patients with a concomitant diagnosis of endo-
carditis were more likely to be male, have a structural
cardiac condition or intravascular device, have a higher
comorbidity score, have presented with anemia as a sen-
tinel symptom, and been diagnosed at earlier stages
(Table 2). Among patients diagnosed with potentially
curable CRC (stages I to III), the concomitant diagnosis of
endocarditis was associated with a higher postoperative
mortality, smaller percentage of patients receiving adjuvant
therapy, higher percentage of patients visiting the emer-
gency department, longer lengths of admissions, longer
stays in intensive care units, and more clinical evaluations
during the first year after CRC diagnosis, compared with
not having endocarditis (Table 3).
Two-year overall survival (95 % CI) was 46.4 % (39.5,
54.5) for stage I–III CRC patients with a concomitant
diagnosis of endocarditis and 73.1 % (72.9, 73.3) for those
without it (risk difference -26.7 %; 95 % CI -33.8,
-19.0). These differences were present across the three
stages (Table 3; Fig. 3). In contrast, the two-year cancer-
specific survival was 84.9 % (79.0, 91.2) for those with a
concomitant diagnosis of endocarditis and 85.7 % (85.5,
85.9) for those without it (risk difference -0.7 %; 95 % CI
-6.8, 5.3). There were no relevant differences by stage
(Table 3; Fig. 3). Compared with no concomitant diagnosis
of endocarditis, the hazard ratio for an endocarditis diag-
nosis was 1.67 (95 % CI 1.42, 1.98) for overall mortality
and 1.24 (95 % CI 0.87, 1.77) for cancer-specific mortality
during a median follow-up of 34 months (interquartile
range, 12–72 months).
Complete information on cancer stage and date of 
diagnosis
N = 750,582
Patients diagnosed with cancer in the years 1992-2009
N = 1,690,873
Not in a HMO in the 12 months before diagnosis
N = 1,391,550
Enrolled in Medicare parts A and B in the 12 months 
before diagnosis
N = 877,918
No IE 12 months before cancer diagnosis
-
Colorectal =
Lung =
Breast =
Prostate =
N           Follow up months IE cases
167,890           10,058,569                568
209,297             6,360,438                270
170,054          13,209,665        380
202,842           15,263,019                617
Patients without cancer, with a reference date within the 
years 1992-2009
N = 740,983
Not in a HMO in the 12 months before reference date
N = 660,021
Enrolled in Medicare parts A and B in the 12 months 
before reference date
N = 277,474 
No IE 12 months before random date
-up N           Follow months IE cases
No cancer =    277,267 23,142,026 758
Fig. 1 Flowchart of individuals’ selection into the study (HMO health maintenance organization, IE infective endocarditis), SEER-Medicare
1992–2009
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Discussion
We found that the incidence of endocarditis in the elderly
increased fivefold around the diagnosis of CRC compared
with the diagnosis of lung, breast, or prostate cancer, or an
arbitrary date for individuals without cancer. An increased
incidence was not observed for other serious infections.
Our study included over five times more CRC patients with
endocarditis than all previous studies combined, and pro-
vided the first estimate of endocarditis incidence sur-
rounding the diagnosis of CRC in the elderly: 19.8 cases
(95 % CI 17.0–22.6) per 100,000 person-months.
The association between endocarditis and CRC diag-
nosis can be due to at least four non-mutually exclusive
Table 1 Incidence rate of
infective endocarditis between
90 days before and 90 days
after diagnosis of colorectal,
lung, breast, and prostate
cancer, SEER-Medicare
1992–2009
Cancer site Persons Person-months Cases Cases per 100,000 person-months (95 % CI)
Unadjusted rate Standardized ratea
Colorectal 167,851 966,072 191 19.8 (17.0–22.6) 19.8 (17.0–22.6)
Lung 209,258 1,163,085 70 6.0 (4.6–7.4) 5.7 (4.2–7.1)
Breast 170,041 1,000,659 17 1.7 (0.9–2.5) 1.9 (1.0–2.8)
Prostate 202,820 1,195,057 44 3.7 (2.6–4.8) 4.1 (2.8–5.4)
Non-cancerb 277,207 1,631,021 37 2.3 (1.5–3.0) 2.4 (1.5–3.2)
a Incidence rate is directly standardized to the age and sex (except for breast and prostate cancer) distri-
bution of CRC patients
b Incidence rate is calculated using a random index date
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Fig. 2 Monthly rates of
infective endocarditis around
diagnosis of colorectal (CRC),
lung, breast and prostate cancer
(PROST), and around a random
date for individuals without
cancer, SEER-Medicare
1992–2009
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Table 2 Characteristics of colorectal cancer patients with and without a concomitant diagnosis of infective endocarditis, SEER-Medicare
1992–2009
No endocarditis (N = 167,699) Endocarditis (N = 191)
Median age (interquartile range) 77 (71–83) 78 (72–83)
Female (%) 53.3 38.2
Race (%)
White 86.5 89.5
African American 8.9 *
Asian/Pacific islander 4.2 *
Other/unknown/unspecified 0.5 *
Comorbidity scorea (%)
0 52.7 39.3
1 21.3 [17.2
2? 14.9 37.7
Unknown 11.0 \5.8
Structural cardiac conditiona (%) 10.6 34.6
Intravascular devicea (%) 3.0 10.5
End stage renal diseasea (%) 0.8 *
Sentinel symptomb (%)
Anemia 26.4 42.9
Gastrointestinal bleeding 24.1 29.3
Gastrointestinal symptoms 17.7 19.9
Large bowel obstruction 2.4 *
Stage (%)
I 26.8 38.2
II 31.5 32.5
III 25.0 19.9
IV 16.8 9.4
Grade of differentiation (%)
Well differentiated 8.9 13.6
Moderately differentiated 63.9 62.3
Poorly differentiated 19.2 17.8
Unknown 8.0 6.3
Location (%)
Ascending colon 35.3 31.4
Transverse colon 14.5 16.7
Descending colon 27.1 26.7
Rectum 23.1 25.1
Urbanicity (%)
Big metro (C1 million) 54.0 58.6
Metro (250,000–1 million) 28.4 29.3
Urban (20,000–250,000) 6.2 *
Less urban (2500–20,000) 9.3 *
Rural (rural or\2500) 2.2 *
SEER registry census region (%)
West 38.2 37.2
Northeast 20.5 34.0
Midwest 19.0 12.0
South 20.7 16.2
Pacific 1.6 *
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Table 2 continued
No endocarditis (N = 167,699) Endocarditis (N = 191)
Year of CRC diagnosis (%)
1992–1996 19.0 18.9
1997–2001 26.1 20.4
2002–2006 30.4 30.9
2007–2010 24.5 29.8
Census tract features [median (interquartile range)]
% did not complete high school 16.7 (10.0–27.1) 15.5 (8.9–24.3)
% below poverty line 8.4 (4.5–15.6) 7.0 (4.0–11.6)
% black race/ethnicity 2.1 (0.6–8.3) 2.1 (0.7–6.7)
% English not well/at all at 65? 1.5 (0–5.4) 2.1 (0–5.9)
Median income (USD) 42,219 (31,906–57,068) 49,131 (35,334–62,316)
* Cells with counts of 11 or lower (B5.8 %) are blinded following SEER-Medicare privacy policy
a Evaluated the 6th month before colorectal cancer diagnosis
b Evaluated during the 3 months preceding colorectal cancer diagnosis
c Missing in 1296 individuals
Table 3 Oncologic management and outcomes in patients diagnosed with stages I–III of colorectal cancer by concomitant diagnosis of infective
endocarditis, SEER-Medicare 1992–2009
No endocarditis
(N = 139,600)
Endocarditis
(N = 173)
Surgery of primary tumor (%) 79.5 84.4
Postoperative mortalitya (%) 6.0 12.0
Adjuvant chemotherapyb (%) 14.5 d
Patients visiting the emergency department during 1st year after CRC diagnosis (%) 50.2 79.2
Median (interquartile range) number of visits 2 (1–3) 2 (1–4)
Patients admitted to a hospital during 1st year after CRC diagnosis (%) 90.3 95.4
Median length of total stayc (interquartile range) 13 (7–27) 43 (25–73)
Median number of days in intensive cared (interquartile range) 0 (0–3) 4 (0–10)
Median number of clinical evaluations during 1st year after CRC diagnosis (interquartile
range)
22 (12–36) 43 (26–66)
Number of deaths 89,172 139
Number of cancer-related deaths 32,945 31
Months of follow-up 9,315,640 8,187
2-year overall survival (%)
Stage I 80.6 (80.2–80.9) 50.6 (38.7–61.4)
Stage II 74.1 (73.7–74.5) 41.4 (29.0–53.4)
Stage III 63.8 (63.4–64.3) 46.9 (30.5–61.8)
2-year CRC-specific survival (%)
Stage I 93.4 (93.2–93.7) 90.0 (79.0–95.0)
Stage II 87.1 (86.8–87.4) 80.9 (66.0–89.8)
Stage III 75.5 (75.1–75.9) 80.1 (60.0–90.8)
a Postoperative mortality defined as death in the 30 days following surgery
b Stages II and III (N = 94,840)
c Sum of days that year through all admissions
d Cells with counts of 11 or lower (B6.4 %) are blinded following SEER-Medicare privacy policy
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reasons, which are summarized in Fig. 4. First, undiag-
nosed CRC (or pre-neoplastic lesions like adenomas) could
cause endocarditis, perhaps by allowing the translocation
of bacteria [17] (Fig. 4a). Second, patients diagnosed with
endocarditis often receive a subsequent colonoscopy as
part of the diagnostic work-up (Supplementary Figure A1),
which could lead to a higher rate of CRC detection
(Fig. 4b). Third, a common causative factor could inde-
pendently lead to CRC diagnosis and endocarditis
(Fig. 4c). For example, colonoscopy could cause both an
increased rate of CRC diagnosis and of endocarditis by
disrupting the bowel mucosal barrier and thus facilitate the
seeding of bacteria in the bloodstream. The colonoscopy
can be performed for screening purposes as shown in
Fig. 4c or as a result of CRC symptoms (i.e. Figure 4c with
an arrow from CRC to colonoscopy). Similarly, the
observed small increase in endocarditis incidence in the
month of lung cancer diagnosis supports the hypothesis that
localized trauma associated with diagnostic procedures (in
this case bronchoscopy) might increase the risk of endo-
carditis. Finally, the association between CRC and endo-
carditis could be due to common etiologic factors such as
immunosuppression, smoking, and alcohol (Fig. 4d).
Regardless of the reason why endocarditis and CRC
diagnosis are associated, CRC patients with concomitant
endocarditis had a 25 % increase in two-year mortality, but
no changes in CRC-specific mortality. This increased
mortality risk suggests that clinicians need to be vigilant
for endocarditis in CRC patients, particularly during the
peri-diagnostic period. Future studies on the risks and
benefits of anti-microbial prophylaxis also could be war-
ranted. Not only did endocarditis increase the risk of non-
cancer specific death, but it also was associated with
changes in cancer treatment. Because decisions on onco-
logic therapies depend on the predicted survival of patients,
our findings will help inform clinical decisions in elderly
patients, an increasing fraction of the oncologic patients
[18, 19] who are under-represented in clinical research
[20]. Our results suggest that the increase in mortality
associated to endocarditis is not through worse oncological
outcomes.
Our study has several limitations. While the quality of
the diagnosis of cancer in SEER-Medicare is high, no
formal validation of endocarditis diagnoses in Medicare
claims has been done. However, endocarditis represents a
serious infection for which patients are unlikely to avoid
care, and an expensive condition for which care is likely to
be well documented in claims data. Further, ICD-9 codes
have been found to be accurate surrogates of bacterial
infections in other administrative datasets [21] and have
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been used as the basis of several studies on endocarditis
[14, 22, 23]. Classifying patients as having a concomitant
diagnosis of endocarditis if they were diagnosed with
endocarditis between 90 days before and 90 days after
cancer diagnosis might introduce a selection bias because
patients that do not survive for at least 90 days after the
date of cancer diagnosis are less likely to be classified in
the endocarditis group. However, only 7 % patients died
during this period and sensitivity analyses using 60 or
120 days instead of 90 days yielded equivalent results
(Supplementary Table A3). Our large database study
lacked bacteriological data, but the pathogen most fre-
quently associated with endocarditis among CRC patients
is Streptococcus gallolyticus subsp. gallolyticus (formerly
Streptococcus bovis I) [3], possibly because of its ability to
translocate through the bowel wall when its permeability is
increased by cancer [24], its immune-evasion properties
[25], and its affinity to the collagen type I in damaged heart
valves [26].
In summary, our study provides a precise estimate of the
association between CRC and endocarditis as well as of the
association between endocarditis and the survival of older
adults with CRC. These findings help inform clinical
decisions for cancer patients, including the diagnostic
workup of patients with CRC and fever of unknown origin,
as well as cost-effectiveness assessments of clinical path-
ways for CRC care.
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